The prognostic role of RASSF1A promoter methylation in breast cancer: A meta-analysis of published data

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Jiang, Yong ^a   Cui, Lin ^a   Chen, Wen de ^a   Shen, Shi hai ^a   Ding, Li dong ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; DISEASE FREE SURVIVAL; FOLLOW UP; GENE; HUMAN; OVERALL SURVIVAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; RASSF1A GENE; SYSTEMATIC REVIEW; BREAST TUMOR; DNA METHYLATION; FEMALE; GENETICS; META ANALYSIS; PATHOLOGY;

BREAST NEOPLASMS; DNA METHYLATION; FEMALE; HUMANS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84861204241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036780     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, et al. (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12: 207.
3. Kim C, Paik S, (2010) Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 7: 340-347.
4. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
5. Muller HM, Fiegl H, Widschwendter A, Widschwendter M, (2004) Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci 1022: 44-49.
6. Agathanggelou A, Cooper WN, Latif F, (2005) Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65: 3497-3508.
7. Dallol A, Cooper WN, Al-Mulla F, Agathanggelou A, Maher ER, et al. (2007) Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities. Cancer Res 67: 492-500.
8. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, et al. (2005) Tumor susceptibility of Rassf1a knockout mice. Cancer Res 65: 92-98.
9. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, et al. (2004) The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6: 129-137.
10. Hesson LB, Cooper WN, Latif F, (2007) The role of RASSF1A methylation in cancer. Dis Markers 23: 73-87.
11. Wang J, Wang B, Chen X, Bi J, (2011) The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 32: 411-416.
12. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, et al. (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15: 1801-1807.
13. Jo H, Kim JW, Kang GH, Park NH, Song YS, et al. (2006) Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol Res 16: 205-209.
14. Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, et al. (2009) RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer 100: 399-404.
15. Martins AT, Monteiro P, Ramalho-Carvalho J, Costa VL, Dinis-Ribeiro M, et al. (2011) High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat 129: 1-9.
16. Kawai Y, Sakano S, Suehiro Y, Okada T, Korenaga Y, et al. (2010) Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann Oncol 21: 1612-1617.
17. Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, et al. (2011) Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat.
18. Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES, (2009) Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Clin Biochem 42: 970-975.
19. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, et al. (2003) DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641-7645.
20. Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, et al. (2011) Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat.
21. Buhmeida A, Merdad A, El-Maghrabi J, Al-Thobaiti F, Ata M, et al. (2011) RASSF1A Methylation is Predictive of Poor Prognosis in Female Breast Cancer in a Background of Overall Low Methylation Frequency. Anticancer Res 31: 2975-2981.
22. Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, et al. (2010) Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol 136: 203-210.
23. Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, et al. (2009) Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol 31: 487-500.
24. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, et al. (2005) Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65: 1141-1145.
25. Hamilton MG, Roldan G, Magliocco A, McIntyre JB, Parney I, et al. (2011) Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J Neurooncol 102: 255-260.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235.
27. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
28. DerSimonian R, (1996) Meta-analysis in the design and monitoring of clinical trials. Stat Med 15: 1237-1248; discussion 1249-1252.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
30. Bax L, Ikeda N, Fukui N, Yaju Y, Tsuruta H, et al. (2009) More than numbers: the power of graphs in meta-analysis. Am J Epidemiol 169: 249-255.